Cybin Corp., Canada’s leading-edge mushroom life-sciences company, has noted its strong support for TheraPsil, a nonprofit coalition that advocates for legal, Special Access Programme (“SAP”) access to psilocybin therapy for palliative care of Canadians. The coalition recently announced that Federal Minister of Health Patty Hajdu has approved the use psilocybin therapy in the end-of-life care for four Canadians diagnosed with incurable cancer. The four are the first publicly known individuals to legally use psilocybin since the compound became illegal in Canada in 1974. “This is a watershed moment for the patients involved who deserve the right to manage their health challenges with dignity,” said Cybin co-founder Paul Glavine in the press release. “Everyone at Cybin applauds the efforts of TheraPsil and these brave individuals, and we thank the Minister of Health for her foresight.”
To view the full press release, visit http://ibn.fm/FAtPL
About Cybin Corp.
Cybin is a life-sciences company advancing mushroom-based psychedelic and nutraceutical products for various psychiatric and neurologic conditions. Cybin is developing technology that seeks to improve bioavailability to achieve the desired effects of psychedelics at lower dosages. Cybin is developing products with new delivery systems and intends to support clinical trials to evaluate efficacy to potentially combat major depressive disorder and addiction and improve cognitive flexibility. For more information about this company, please visit www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
